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INTRODUCTION 
Diabetes mellitus is a complex metabolic condition defined by level 
of hyperglycemia giving rise to micro vascular and macro vascular 
complications1.Current estimates suggests that there are 170 million people 
suffering from DM world wide and this number is going upto 266 million 
by 20302.The prevalence of DM in India is around 31 million  and this 
number will increase to 80 million by 20302. Indians develop diabetes at 
younger age, with lower degree of obesity and have increased risk of 
chronic diabetic complications.Hence DM is a major public concern in 
India.Various complications related to micro or macro vascular diseases like 
retinopathy,nephropathy, neuropathy,ischemic heart diseases and peripheral 
vascular disease have been reported. Liver diseases is often overlooked as a 
complication of DM. 
Infact VERONA-DIABETES POPULATION BASED STUDY has 
shown that among patients with DM standardised mortality rate from 
cirrhosis was higher than cardiovascular diseases3.Though association of 
diabetes with cirrhosis has been recognised for more than 100 yrs, liver 
diseases in diabetes remains under estimated4.  
Abnormal liver function test results are more common in diabetes 
mellitus than in the non diabetic population as well as in patients with type 2 
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diabetes than in those with type 1 diabetes. Elevated activities of the two 
serum transaminases; alanine transaminase (ALT) and aspartate 
transaminase (AST) may be associated with liver disease. Elevation of these 
enzymes is strongly related to obesity, diabetes and dyslipidemia, and their 
measurement may act as a surrogate marker of NAFLD presence. 
This study was conducted to estimate the prevalence of elevated liver 
transaminase levels among patients with type 2 diabetes and to determine 
the associated risk factors.  
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AIM OF THE STUDY 
The aim of this study was to determine prevalence of abnormal liver 
function test in patients with type 2 diabetes and to determine associated 
risk factors. 
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REVIEW OF LITERATURE 
Diabetes mellitus is known to be associated with a number of liver 
disorders including isolated elevation of liver enzyme levels, nonalcoholic 
fatty liver disease (NAFLD), and other chronic liver disorders like hepatitis 
C infection (HCV), cirrhosis and hepatocellular carcinoma3,5,6. Abnormal 
liver function test results are more common in diabetes mellitus than in the 
non diabetic population as well as in patients with type 2 diabetes than in 
those with type 1 diabetes. Elevated activities of the two serum 
transaminases; alanine transaminase (ALT) and aspartate transaminase 
(AST) may be associated with liver disease. Elevation of these enzymes is 
strongly related to obesity, diabetes and dyslipidemia, and their 
measurement may act as a surrogate marker of NAFLD presence.3,7 Of the 
two enzymes, ALT appears to have a role in gluconeogenesis,8 and seems to 
be more related to liver fat accumulation than AST.9 Some authors have 
suggested that minor elevation of this enzyme's level may be a good 
predictor of mortality from liver disease. 10 A study of the association of 
serum ALT activity and ten-years' risk of cardiovascular disease in 
participants of the Third National Health and Nutrition Examination Survey 
(NHANES- III) had reported that those with elevated ALT levels had a 
higher calculated cardiovascular disease risk than those with normal ALT 
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activity, if viral hepatitis or excessive alcohol consumption were 
excluded. 11  
The activity of ALT in the hepatocytes is 7000 fold greater than in the 
serum, 12 and this abundance is the reason for using it as a marker for 
NAFLD in many epidemiological studies.  Clark et al.13 proposed that 
elevated AST or ALT levels are predictive of the presence of NAFLD if two 
basic criteria are met: 1) exclusion of alternative chronic liver diseases, e.g. 
alcoholic liver disease, hepatitis B or C infection, and hemochromatosis; 
and 2) presence of features of the metabolic syndrome.  
SPECTRUM OF LIVER DISEASES IN DIABETES: 
ESTABLISHED PROPOSED 
NAFLD 
NASH 
NASH WITH CIRRRHOSIS 
CRYPTOGENIC CIRRHOSIS 
HEPATOCELLULAR 
CARCINOMA 
GLYCOGENIC HEPATOPATHY 
DIABETIC HEPATOSCLEROSIS 
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DIABETES AND LIVER DISEASE: 
1. Liver diseases causes diabetes 
2. Diabetes contributes to or cause liver diseases 
3. Risk factor for liver disease and diabetes are same e.g.alcoholic liver 
disease with alcoholic chronic pancreatitis. 
IMPACT OF DIABETES ON LIVER DISEASE: 
CONDITION INCIDENCE LEVEL OF 
EVIDENCE 
ACUTE LIVER FAILURE 
CHRONIC LIVER DISEASES 
 
CIRRHOSIS 
HEPATOCELLULAR 
CARCINOMA 
MORTALITY DUE TO LIVER 
DISEASES 
INCREASED 
INCREASED 
 
INCREASED 
INCREASED 
 
INCREASED 
3a 
2a 
 
2a 
1a 
 
2a 
 
DIABETES DUE TO LIVER DISEASES: 
Cirrhosis is associated with impaired glucose tolerance in more than 
80% of patients19 .Overt diabetes is seen around 20% of cirrhotics. 
Pathogenesis of diabetes and cirrhosis include peripheral and hepatic insulin 
resistance and decreased beta cell function.Increased mortality and 
increased risk of HCC has been shown  in patients who develop diabetes.20  
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THEORIES BEHIND LFT ELEVATION IN DIABETES: 
The liver helps maintain normal blood glucose concentration in the 
fasting and postprandial states. Loss of insulin effect on the liver leads to 
glycogenolysis and an increase in hepatic glucose production. Abnormalities 
of triglyceride storage and lipolysis in insulin-sensitive tissues such as the 
liver are an early manifestation of conditions characterized by insulin 
resistance and are detectable earlier than fasting hyperglycemia. The precise 
genetic, environmental, and metabolic factors and sequence of events that 
lead to the underlying insulin resistance, however, is not fully understood.14 
In animal models, chronic hyperinsulinemia is found to predispose 
the liver to relative resistance to insulin. This is characterized by a failure of 
insulin to signal an increase in insulin receptor substrate-2. Upregulation of 
sterol regulatory element-binding protein 1c (SREBP-1c) also occurs, 
leading to increased lipogenesis.15 Despite down-regulation of the insulin 
receptor substrate-2-mediated insulin signaling pathway in insulin-resistant 
states, the up-regulation of SREBP-1c and subsequent simulation of de novo 
lipogenesis in the liver leads to increased intracellular availability of 
triglycerides, promoting fatty liver. This also increases VLDL assembly and 
secretion.14 Thus, hyperinsulinemia might directly lead to hepatic insulin 
resistance with associated fatty changes.  
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The excess in free fatty acids found in the insulin-resistant state is 
known to be directly toxic to hepatocytes. Putative mechanisms include cell 
membrane disruption at high concentration, mitochondrial dysfunction, 
toxin formation, and activation and inhibition of key steps in the regulation 
of metabolism.16 Other potential explanations for elevated transaminases in 
insulin-resistant states include oxidant stress from reactive lipid 
peroxidation, peroxisomal beta-oxidation, and recruited inflammatory cells. 
The insulin-resistant state is also characterized by an increase in 
proinflammatory cytokines such as tumor necrosis factor-α (TNF-α), which 
may also contribute to hepatocellular injury. In preliminary studies, an 
increased frequency of specific TNF-α-promoter polymorphism was found 
in nonalcoholic steatohepatitis (NASH) patients, suggesting a possible 
genetic link or predisposition to fatty liver found in insulin-resistant states.17 
The above theories all attribute elevated transaminases  to direct 
hepatocyte injury. It is also hypothesized that elevation in ALT, a 
gluconeogenic enzyme whose gene transcription is suppressed by insulin, 
could indicate an impairment in insulin signaling rather than purely 
hepatocyte injury18. 
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NON ALCOHOLIC FATTY LIVER DISEASE 
NAFLD is  the most common etiology of chronically elevated LFTs 
in the United States in both diabetic and nondiabetic individuals.17 The 
estimated prevalence of aminotransferase elevations in the general 
population from the third National Health and Nutrition Examination 
Survey data is 7.9%, with about two-thirds of cases unexplained. Of the 
unexplained cases, most are strongly associated with metabolic syndrome 
and probably represent underlying NAFLD. 
Currently NASH is considered to be hepatic manifestation of 
metabolic syndrome.21 Patients with NAFLD have an increased risk of 
cardiovascular and liver morbidity.22-23Diabetic patients  with NAFLD are at 
increased risk of advanced liver diseases, cirrhosis and HCC. NAFLD is an 
important cause of cryptogenic cirrhosis.17-26   
NAFLD is a clinicopathological condition representing a spectrum of 
histological findings from simple hepatic steatosis  or steatosis with mild  
inflammation(type 1 & 2), to hepatic steatosis with a necroinflammatory 
component that may or may not have fibrosis, or NASH(type 3 & 4). Type 1 
& 2 infrequently progress to cirrhosis, whereas type 3 & 4 progress to 
cirrhosis in 15 -30 % of patients.NAFLD has become a common cause of 
liver transplant in US.It has also been associated  identified as an important 
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risk factor for development of primary liver cancer mostly due  to NAFLD 
associated cirrhosis. 
DEFINITION AND TERMS: 
NON ALCOHOLIC FATTY LIVER DISEASES: 
Presence of fatty infiltration of liver as exceeding 5 % weight and 
frequently taken as fat in >5—10% of macrosteatotic hepatocyte in biopsy 
specimen. 
PRIMARY NASH:  
The term is occasionally encountered in literature but not widely 
accepted. It indicates NASH associated with central obesity and often type 2 
diabetes, but without a specific, additional etiological factors. 
SECONDARY NASH: 
NASH associated with a specific problem such as effect of a drug or 
bariatric surgery. 
PRESUMED NASH or NAFLD: 
In several epidemiological and pediatric studies, NASH has been used 
as presumptive diagnosis because of abnormal liver enzyme levels, negative 
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results of viral studies and echogenic or bright liver at USG consistent with 
fatty infiltration. 
PATHOGENESIS OF NAFLD 
The most-recognized proposal for the pathogenesis of NASH is a 
"two-hit" hypothesis.24 Hepatic fat accumulation in the liver due to insulin 
resistance and subsequent hyperinsulinemia represents the "first hit," which 
induces a "second hit" including  oxidative stress, and increased cytokine 
release. These modifications enhance lipid peroxidation, hepatocyte injury, 
and release of toxic byproducts, resulting in necroinflammation and fibrosis.   
Another important pathogenic culprit is adipocytokines secreted by 
the white adipose tissue (WAT) related to visceral obesity. White adipose 
tissue is now recognized as an endocrine organ that secretes several 
adipokines and cytokines including adiponectin, leptin, resistin, and visfatin, 
TNF-α, interleukin-6 and angiotensinogen.25 Adiponectin is an adipokine 
that is decreased in obesity. Furthermore, plasma adiponectin levels are 
decreased in NAFLD, whereas exogenous adiponectin improves hepatic 
steatosis in animal models of non-alcoholic fatty liver.25 The pro-
inflammatory cytokine, TNF-α, is increased in NAFLD patients and therapy 
directed against it can be beneficial.26  There is evidence that leptin 
modulates insulin secretion and insulin activity, but insulin on the other 
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hand can also regulate leptin expression. Liver, skeletal muscle and 
adipocytes express leptin receptors. Although leptin increases insulin 
sensitivity in rats, it increased hepatic insulin resistance in humans by 
decreasing phosphorylation of insulin receptor substrate. Moreover, serum 
leptin levels correlated with steatosis in patients with NASH but do not 
correlate with hepatic fibrosis in humans. Resistin is a recently identified 
adipokine causing insulin resistance.27 
 Further studies are needed to define the pathogenesis of NAFLD 
clearly and explain the apparent interindividual variation in the 
susceptibility to progress to more-advanced liver disease. Genetic factors 
have been suggested to play an important role in this variation, and several 
new candidate genes have been proposed. 
CONDITIONS ASSOCIATED WITH NON ALCOHOLIC FATTY 
LIVER  
Insulin resistance  
a. Syndrome X 
o Obesity 
o Diabetes 
o Hypertriglyceridemia 
o Hypertension 
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b. Lipoatrophy 
c. Mauriac syndrome 
Disorders of lipid metabolism  
a. Abetalipoproteinemia 
b. Hypobetalipoproteinemia 
c. Andersen's disease 
d. Weber-Christian syndrome 
Total parenteral nutrition 
Bariatric surgery 
      a.jejuno ileal bypass 
      b.gastric bypass or gastroplasty 
Iatrogenic  
a. Amiodarone 
b. Diltiazem 
c. Tamoxifen 
d. Steroids 
e. Highly active antiretroviral therapy 
f. Refeeding syndrome  
Toxic exposure(carbontetrachloride,perchloroethylene,phosphorus, ethyl 
bromide) 
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SIGNS AND SYMPTOMS: 
The signs and symptoms of nonalcoholic fatty liver disease (NAFLD) 
vary widely, depending on the stage of the condition.The majority of 
individuals with NAFLD have no symptoms and a normal examination. 
Children may exhibit symptoms such as abdominal pain, which may be in 
the center or the right upper part of the abdomen, and sometimes fatigue. 
However, other causes of abdominal pain and fatigue should be considered. 
On physical examination the liver might be slightly enlarged and some 
children may have patchy, dark discoloration of the skin present (acanthosis 
nigricans) most commonly over the neck and the under arm area... However, 
as the disease advances, patients may experience symptoms of cirrhosis.  
LABORATORY FINDINGS: 
In a patient with suspected NAFLD or NASH, useful baseline testing 
should include levels of AST, ALT, total and direct bilirubin, and fasting 
serum glucose, as well as a lipid panel. Mild to moderate elevation of serum 
aminotransferase levels is most commonly found (mean range, 100-
200 IU/L). Generally, the ratio of AST to ALT is less than 1, but this ratio 
increases as fibrosis advances. Liver enzyme levels are normal in a large 
percentage of patients with NAFLD; normal aminotransaminase levels do 
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not exclude the presence of advanced disease. Serum alkaline phosphatase 
and γ-glutamyl transpeptidase levels may also be mildly abnormal.  
Given that more than 80% of patients with NAFLD have some 
components of the metabolic syndrome, serum levels of fasting cholesterol 
and triglycerides, as well as fasting glucose and insulin, should be 
determined. Albumin, bilirubin, and platelet levels are usually normal unless 
the disease has evolved to cirrhosis. There is elevation of serum IgA and 
lowering of serum IgG/IgA.Some patients with NAFLD have low titers of 
autoimmune antibodies (antinuclear and anti–smooth muscle antibody) and 
an elevation of ferritin. The role of these markers is still unclear. 
IMAGING: 
A liver ultrasound examination is useful for confirming steatosis. 
Fatty infiltration of the liver produces a diffuse increase in echogenicity and 
vascular blurring. Unfortunately, ultrasound cannot rule out steatohepatitis 
or fibrosis, and its sensitivity drops sharply when less than 30% of 
hepatocytes contain fat droplets.  
Both computed tomography (CT) and magnetic resonance imaging 
(MRI) studies, especially the new technique of magnetic resonance 
spectroscopy, are more sensitive modalities for quantifying steatosis. 
However, none of these imaging techniques has sufficient sensitivity and 
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specificity for staging the disease and cannot distinguish between simple 
bland steatosis and NASH with or without fibrosis. 
LIVER BIOPSY: 
Liver biopsy is of unquestioned value in determining the presence of 
steatosis, distinguishing steatosis from steatohepatitis, and assessing the 
degree of fibrosis. Because the diagnostic accuracy of noninvasive 
diagnostic tools is low, histology is the most reliable means to grade the 
severity of the disease and thus estimate prognosis. Biopsy is also helpful in 
ruling out an alternative diagnosis. In addition to establishing the cause and 
severity of disease, histology permits the monitoring of disease progression 
and the response to therapy, because aminotransaminase levels can decrease 
during the course of the disease regardless of whether fibrosis progresses or 
improves. 
STAGING FIBROSIS OF NASH 
Stage Histologic description 
0 No fibrosis 
1 Zone 3 perisinusoidal fibrosis only
2 Zone 3 plus portal/periportal fibrosis 
3 As above with bridging fibrosis 
4 Cirrhosis 
 Adapted from Brunt et al. 28 
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NASH ACTIVITY GRADE 
 L=lobular, P=portal. 
 Adapted from Brunt et al. 28 
 
THERAPY FOR NON ALCOHOLIC FATTY LIVER DISEASES: 
There is no proven therapy for NAFLD.Patients with simple steatosis 
probably need only observation with regard to liver disease ,although 
associated condition may warrant consideration of probable toxicity of 
common agents such as antihypertensives, anti lipidemics and anti diabetic 
medications.For patients  with mild inflammation and no  fibrosis ,a less 
aggressive observational approach is required because the prognosis appears 
to be relatively good. A  more directed therapy is required if fibrosis is 
present at biopsy. 
 
 
Grade Steatosis Ballooning Inflammation 
Mild, Grade 1 1–2 (up to 33%) Minimal L:1–2  P: none-mild 
Moderate, Grade 2 2–3(>33%-66%) Present L:2  P:mild-moderate 
Severe, Grade 3 3(>66 %) Marked L:3  P:mild-moderate 
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DIETARY WEIGHT LOSS AND EXERCISE: 
The most practical and most commonly recommended therapy is 
exercise, diet and weight loss. Weight loss may be associated with 
progression of liver diseases, especially if the rate of weight loss is more 
than 1.6 kg per week.Some studies have shown improvement in liver 
enzyme values, in histologic findings and degree of steatosis, however 
fibrosis was not significantly altered. 
WEIGHT REDUCTION SURGERY: 
Roux en y gastric bypass procedure remains popular weight loss 
procedure for overweight patients, even though it carries a risk of hepatic 
decompensation .In patients undergoing sustained weight loss after this 
procedure, plasma glucose, triglycerides, ALT levels are usually reduced. 
Liver biopsy showed reduction in degree of steatosis, however fibrosis was 
not significantly altered. 
URSODEOXYCHOLIC ACID AND CYTOPROTECTIVE  
AGENTS: 
          Initial studies involving people with NASH have shown that treatment 
with UDCA can lead to improvements in liver enzymes and to a reduction 
in the severity of fatty deposits in the liver. The potential benefits of UDCA 
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may be derived from effects on mitochondrial membrane stability, 
improvement in blood flow or immune modulation UDCA may possibly 
decrease the risk of developing gallstones during weight reduction. Further 
studies are ongoing as to the effects of UDCA on NAFLD. 
ANTI HYPERLIPIDEMIC AGENTS:   
Clofibrate, a triglyceride-lowering drug, has been tested as a 
treatment but has not shown to be beneficial. Gemfibrozil, another 
triglyceride-lowering medication was able to improve liver enzyme 
elevations in a small group of people with NAFLD, but its effects on liver 
fat and scarring was not tested.  Further study is needed on 
gemfibrozil.There is less rationale in using HMGCoA reductase  however 
they can be safely prescribed for conventional indications .Importantly there 
is no evidence that patients with pre existing NAFLD are at increased risk of 
statin induced idiosyncratic hepatatoxicity  or statins associated with higher 
frequency of hepatic steatosis. 
ANTI DIABETIC DRUGS: 
Metformin, is an insulin sensitizing agent used extensively to treat 
DM2. The drug was studied in a small series of NASH patients and showed 
beneficial effects on transaminases and decreased fatty infiltration in the 
liver. A larger trial is ongoing.  
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Thiazolidinediones. Among the thiazolidinediones, troglitazone was the first 
to be studied in NASH patients, who showed some biochemical 
improvement;29 however, troglitazone was subsequently withdrawn due to 
hepatotoxicity. The potential of two newer types of thiazolidinedione–
rosiglitazone and pioglitazone–to treat patients with NASH has since been 
assessed. Both rosiglitazone and pioglitazone have been shown to improve 
liver enzyme levels and liver histology.30-32 Although histologic 
improvement occurred with pioglitazone treatment, however, a significant 
reduction in fibrosis was not seen.31 It also seems that the improvement 
generated by rosiglitazone and pioglitazone is short lasting, and liver 
enzyme levels become abnormal again once these medications have been 
discontinued. There remains concern associated with thiazolidinedione 
treatment as these drugs do have the potential for toxicity32 and patients tend 
to gain weight on treatment. Furthermore, because these studies were 
conducted with relatively small numbers of individuals and over short time 
periods, well-controlled clinical trials are needed to establish their efficacy. 
ANTIOBESITY MEDICATIONS: 
In one study, orlistat (an enteric lipase inhibitor) has been shown to 
promote weight loss and to reduce aminotransferase levels, with improved 
liver histology in 9 out of 10 NAFLD patients.33 Sibutramine (a selective 
serotonin reuptake inhibitor) has been compared with orlistat;34 both 
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treatment groups lost weight and improvements were demonstrated in both 
liver enzyme levels and in the extent of steatosis visible on ultrasound. 
Despite these encouraging findings, questions remain as to whether these 
medications can be tolerated long term by patients and whether sustained 
weight loss can be achieved.35 
ANTIOXIDANTS AND NUTRITIONAL SUPPLEMENTS: 
One preliminary study has indicated that vitamin E (alpha-tocopherol) 
supplementation may be a beneficial adjunctive treatment for people with 
NAFLD, but more research is needed in this area. 
Betaine is a precursor of S-adenosyl methionine (SAMe), a derivative 
of the amino acid methionine.  S-AMe is purported to promote the health of 
the liver.  In two studies, some patients who were treated with betaine 
experienced decreased liver enzyme elevations and a decreased  amount of 
fatty deposits in their livers.  The mechanism by which betaine exerts its 
beneficial effect on the liver, is not clear, but it is believed that it may assist 
in transporting fat away from the liver. More research is needed in this area. 
Certain nutritional deficiencies which are common among people 
with NAFLD may provide a clue in the search for a successful treatment. 
Some people who receive intravenous feedings for prolonged periods of 
time develop fatty liver in addition to a choline deficiency. Correcting the 
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choline deficiency in these people has been shown to resolve the fatty liver 
as well. Choline supplementation in people with NAFLD is a promising 
treatment option, but is one which requires further study. 
OTHER MEDICATIONS: 
Other medications, such as pentoxifylline (Pentoxil, Trental), 
probiotics, and angiotensin-converting enzyme inhibitors, have been used in 
small studies of patients with NASH, with encouraging but inconclusive 
results. 
LIVER TRANSPLANTATION: 
In patients with decompensated NAFLD cirrhosis, liver 
transplantation should be considered. Coexisting conditions (e.g., morbid 
obesity, severe complications of diabetes, cardiac disease) and fear of 
intraoperative and post-transplantation complications, may preclude 
transplantation candidacy in these patients. A thorough pretransplantation 
evaluation, as well as better weight and metabolic derangement control, may 
be necessary. Following transplant, most patients have persistent metabolic 
syndrome, with long-term implications. Moreover, NAFLD has been shown 
to recur in the liver allograft, with a possible rapid progression to 
steatohepatitis and cirrhosis. 
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GLYCOGENIC HEPATOPATHY 
Glycogenic hepatopathy results from the pathologic accumulation of 
excess glycogen within the liver and is most commonly associated with 
poorly controlled type I diabetes mellitus. Additional patient groups that can 
be affected by glycogenic hepatopathy include those with type II diabetes 
mellitus, urea cycle defects, and drug effect. Glycogenic hepatopathy was 
first described by Mauriac as a part of syndrome including growth 
retardation, cushingoid habitus and delayed puberty36.It is now becoming 
clear that liver defect in Mauriac syndrome can occur without syndromal 
features in adults with type 1 DM 37–adult variant Mauriac syndrome. 
PATHOGENESIS OF GH: 
An essential element in pathophysiology of GH is wide fluctuation in 
both insulin and  glucose levels. High serum glucose levels causes an insulin 
independent inflow of glucose in hepatocytes where it is rapidly 
phosphorylated, trapping it in cell.Subsequent treatment of high glucose 
level  with insulin  causes the trapped glucose to polymerise to 
glycogen38.Glycogen production persist for sometime after insulin have 
declined.Thus alteration in high glucose and insulin level in poorly 
controlled DM causes GH. 
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CLINICAL FEATURE AND LAB INVESTIGATION: 
  The clinical presentation typically includes varying degrees of 
hepatomegaly, abdominal pain, and elevated transaminases. Occasionally, 
the transaminase elevations can be dramatic and reach levels of greater than 
10 times the upper limit of normal. The liver shows diffusely pale staining 
hepatocytes on routine H&E stains and excessive glycogen accumulation on 
PAS stains. Abundant glycogenated nuclei and megamitochondria can be 
seen, but there should be little or no inflammation, mild or absent fatty 
change, and no significant fibrosis. 
TREATMENT OF GH: 
Treatment consist of improving glycemic control.  Adequate control 
of glucose and insulin level causes complete recovery of clinical, 
biochemical and histological abnormalities. 
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HEPATITIS C VIRUS AND TYPE 2 DIABETES MELLITUS: 
Hepatitis C virus (HCV), the leading cause of liver disease in the 
United States, is a known independent predictor of type 2 diabetes, the most 
common endocrine disease even in patients without cirrhosis39-40. HCV is 
known to have a higher prevalence within diabetic patients. When 
comparing 176 diabetic patients to 6,172 blood donors matched for 
recognized risk factors of acquiring HCV, there was a higher prevalence of 
HCV infection within the diabetic patients (11.5 vs. 2.5%, P<0.001).17 Of 
the diabetic patients with HCV, 72.3% had abnormally elevated LFTs, 
compared to 27.7% of diabetic patients without evidence of HCV  
(P< 0.001)41. Post liver and renal transplant increase incidence of diabetes is 
correlated with HCV infection. 
The proposed mechanism of HCV related DM suggest role of viral 
mediated hepatic and peripheral insulin resistance ,up regulation of TNF 
alpha production and beta cell dysfunction.Development of DM also 
depends on hepatic parenchymal damage and fibrosis. 
  This would suggest that any diabetic patient with elevated LFTs 
needs screening for HCV. 
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DIABETIC HEPATOSCLEROSIS 
Diabetic hepatosclerosis is recently described as micro vascular 
disease manifested by increased alkaline phosphatase and deposition of 
collagen and basement membrane in the perisinusoidal space. 
Collagenization of space of disse positively correlates with the diabetic 
microangiopathy. The prevalence and clinical significance of DHS is still 
unclear.DHS may represent a hepatic form of microvascular disease in 
DM42.  
DIABETES AND HEPATOCELLULAR CARCINOMA 
DM is identified as a risk factor for HCC.DM is shown to increase the 
risk of HCC by two to four folds even after adjusting for other predisposing 
factors.In a prospective case control study they have demonstrated DM is 
associated with more advanced HCC and poor outcome.Diabetes appears to 
increase the recurrence of HCC after potentially curative therapy regardless 
of etiology of liver disease43,44,45,46. 
POST TRANSPLANT DIABETES MELLITUS 
Incidence post liver transplant DM is reported to be from 4% to 
31%.Post transplant DM may be associated with HCV, alcoholic cirrhosis, 
immunosuppressive medication like cyclosporine, tacrolimus, 
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corticosteroids. Post transplant morbidity and mortality is increased in 
patients who developed diabetes47.48. 
STATINS IN TYPE 2 DM PATIENTS WITH ELEVATED 
TRANSMINASES 
High-dose statin therapy is associated with more frequent 
abnormalities of LFTs, although they are generally still relatively 
infrequent. In the Treating to New Targets (TNT) trial,49 patients with 
clinical cardiovascular disease (CVD) were randomized to 10 or 80 mg of 
atorvastatin. The incidence of persistent elevation in ALT, AST, or both 
(defined as two consecutive measurements obtained 4-10 days apart that 
were more than three times the upper limit of the normal range) was 0.2 and 
1.2%, respectively (P < 0.001).49 
Because of large trials such as these, current recommendations from 
the American College of Physicians suggest that type 2 diabetic patients 
with other cardiovascular risk factors should take a statin for primary 
prevention of macrovascular complications. These patients do not need 
routine monitoring of LFTs while on statins unless they have baseline 
abnormalities in LFTs, myopathy, or are taking other drugs that could 
increase their risk of adverse events.50 
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For diabetic patients with baseline transaminases less than three times 
the upper limit of normal, it is not contraindicated to initiate, continue, or 
advance statin therapy as long as patients are carefully monitored.51 The 
frequency of required monitoring in these patients is under debate. There is 
also a debate as to whether transaminase elevation in statin therapy even 
constitutes true hepatoxicity.51 For diabetic patients over the age of 40 years, 
and certainly in the setting of multiple cardiovascular risk factors or known 
CVD, the potential risk of statin therapy from the perspective of 
hepatotoxicity is far outweighed by the proven benefit from CVD risk 
reduction. 
ORAL DIABETIC AGENTS IN TYPE 2 DIABETES MELLITUS 
PATIENTS WITH ELEVATED TRANSMINASES 
The introduction of the insulin sensitizer troglitazone and subsequent 
cases of hepatotoxicity led Jick et al.52 to investigate the baseline risk of 
liver disease in type 2 diabetic patients on oral agents other than 
thiazolidinediones.52  
Lebovitz et al.53 studied more than 6,000 patients with type 2 diabetes 
in a double-blind clinical trial using various doses of rosiglitazone, placebo, 
and either glyburide, metformin, or insulin. Mean HBA1C levels at the start 
of the study were similar across all groups (8.5-9%).  Measurement of liver 
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enzymes occurred at screening, baseline, then every 4 weeks for the first 3 
months of treatment and at 6- to 12-week intervals thereafter. Patients were 
excluded from the study if they had ALT, AST, or ALP greater than two 
and a half times the upper limit of normal at screening. This is consistent 
with current recommendations of when not to use rosiglitazone or 
pioglitazone.  
Of those on rosiglitazone, ׽3,800 were monitored for at least 6 
months, 2,800 for at least 1 year, and 1,000 for at least 2 years. No evidence 
of hepatotoxic effects were observed in the 5,006 patients who took 
rosiglitazone. The percentage of patients who developed ALT greater than 
three times the upper limit of normal were 0.32% of the rosiglitazone group, 
0.17% of the placebo group, and 0.40% for the group taking either 
sulfonylurea, metformin, or insulin. The respective incidence rates of 0.29, 
0.59, and 0.64/100 person-years show no difference between treatment of 
rosiglitazone, placebo, and other antihyperglycemic agents and the 
development of ALT levels greater than three times the upper limit of 
normal. Furthermore, of the 5.6% of the patients whose serum ALT values 
were between one and two and a half times the upper limit of normal at 
baseline, 66% of those treated with antihyperglycemic medicines 
normalized their ALTs, whereas only 38.7% of those treated with placebo 
normalized ALT levels.53 This supports the important link among glycemic 
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control, insulin resistance, and hepatic function and suggests that improved 
glycemic control and improvement in insulin resistance can reduce mild 
chronic elevation of transaminases often found in diabetic patients. The 
decrease in LFTs demonstrated with rosiglitazone and pioglitazone therapy 
in diabetic patients has also been shown in pilot studies using 
thiadolidinediones to treat NASH, a surrogate for insulin resistance.  
CAN ELEVATED LFTs PREDICT THE DEVELOPMENT OF 
DIABETES MELLITUS? 
GGT is a nonspecific marker that is known to rise in patients with 
type 2 diabetes. In epidemiological studies, it has a positive association with 
alcohol intake, cigarette smoking, coronary heart disease, BMI, systolic 
blood pressure, serum triglyceride, heart rate, uric acid, and hematocrit. It 
has an inverse association with physical activity level.54 Because GGT 
increases in diabetes, and increases as BMI increases, it has been proposed 
as another marker of insulin resistance.  
To determine whether elevated GGT could predict the development 
of type 2 diabetes, a prospective cohort study of 7,458 nondiabetic men 
aged 40-59 years was conducted for 12 years.55 Mean serum GGT at the 
start of the study was significantly higher in the 194 men who developed 
type 2 diabetes than in the rest of the cohort who did not develop diabetes 
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(20.9 vs. 15.3 units/l, P < 0.0001). The association was independent of 
serum glucose and BMI.   
Ohlson et al.56 found elevated ALT in nondiabetic Swedish men to be 
a risk factor for type 2 diabetes, independent of obesity, body fat 
distribution, plasma glucose, lipid, AST, bilirubin concentrations, and 
family history of diabetes.  
With similar results, Vozaroza et al.57 followed 451 nondiabetic Pima 
Indians for an average of 6.9 years to determine whether hepatic enzyme 
elevations could be linked to the development of type 2 diabetes. At 
baseline, ALT, AST, and GGT were related to percent body fat. After 
adjustment for age, sex, body fat, whole body insulin sensitivity, and acute 
insulin response, only elevated ALT at baseline was associated with an 
increase in hepatic glucose output. Prospectively, increasing ALT 
concentrations were associated with a decline in hepatic insulin sensitivity 
and risk of type 2 diabetes.  
The authors concluded that higher ALT is a risk factor for type 2 
diabetes and indicates a potential role of increased hepatic gluconeogenesis 
and/or inflammation in the pathogenesis of type 2 diabetes. 
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MATERIALS AND METHODS 
The study was conducted in Government Royapettah hospital 
between January 2009 to June 2010. It was a cross sectional study in which 
patients were interviewed and their data were recorded in a standardized 
proforma. Data collected included age, gender, duration of diabetes, drug 
history and co-morbid conditions like hypertension and coronary heart 
diseases etc. Patients were asked for history of alcohol consumption and the 
medications used, mainly hepatotoxic drugs as steroids, antiepileptics, 
amiodarone and antineoplastic drugs. The study was approved by the Ethics 
Committee  and written informed consent obtained from all participants.  
The following are the patients inclusion and exclusion criterias. 
INCLUSION CRITERIA: 
              Presence of type 2 diabetes mellitus of any duration. 
EXCLUSION CRITERIA: 
    1. Consumption of alcohol. 
    2. Seropositivity of HbsAg and antiHCV  antibody. 
    3. Seropositivity  of HIV ELISA. 
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    4.  Patient on drugs  that are proven to cause  steatohepatitis (steroids, 
amiodarone, oral contraceptive pills, and other estrogen                     
containing preparations). 
5. Patients with renal failure. 
A total of 160 type 2 diabetic patients who met the inclusion criteria 
were studied during this period. Both inpatients and outpatients attending 
diabetology outpatient department were included in the study. 
Body weight was taken while the patients barefooted and in light 
clothing, using a weighing scale with accuracy of ±100 g. Standing height 
was measured without shoes to the nearest cm  with the shoulders in a 
relaxed position and the arms hanging freely. Body mass index. (BMI) 
(kg/m 2 ) was calculated as the ratio of weight (kilograms) to the square of 
height (meters). Patients' BMI was classified according to WHO 
classification,  as being normal (BMI; 18.5 to 24.9 kg/m 2 ), overweight 
(BMI; 25 to 29.9 kg/m 2 ) or obese (BMI>30 kg/m 2 ). 
 Waist circumference and hip circumference was measured in a 
standing position using non stretchable tailor measuring tape to look for 
central obesity.   Central obesity is defined in men by a waist-to-hip 
circumference ratio greater than 1.0 or a waist circumference greater than 40 
inches (102 centimeters). In women, central obesity is defined by a waist-to-
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hip ratio greater than 0.8 or a waist circumference greater than 35inches (88 
centimeters).  
   All the above patients were examined and screened for HbsAg, 
antiHCV antibody, HIV ELISA and were found to be negative. Morning 
samples of venous blood were collected from patients after fasting for at 
least 14 hours and tested for glucose, urea, creatinine (using semi auto 
analyzer Merck 300), hemoglobin A1C (HbA1C) [Using High Performance 
Liquid Chromatography method], for the liver enzymes; ALT and AST 
[Using semi auto analyzer Merck 300], and for lipid profile including total 
cholesterol (TC), high density lipoprotein (HDL), triglycerides (TGL), and 
low density lipoprotein (LDL)[ Using semi auto analyzer Merck 300]  and 
serum protein, albumin, globulin(Using calorimetry photochem -5). 
Elevated ALT and AST levels were defined as enzyme activity >40 U/L 
respectively, according to the clinical assay adopted by the center's 
laboratory.. 
 Ultrasound abdomen was done for all patients, to look for size of the 
liver, echogenecity of liver parenchyma, any evidence of chronic liver 
disease like coarse echotexture of liver, dilated portal vein and/or 
splenomegaly. The diagnosis of fatty liver was based on a diffuse 
hyperechoic echotexture (bright liver) and increased liver echotexture 
compared with the kidneys. 
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Statistical analysis: 
Data analysis was performed using the Statistical Package for Social 
Sciences (SPSS). The chi-square (χ2 ) test  was used to determine the 
association of elevated ALT and AST levels with different variables. A two-
tailed P value of 0.05 was considered statistically significant. 
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RESULTS 
A total of 160 type 2 DM patients (male =65 pts and female =95 pts)   
who met the inclusion criteria were studied during the study period. Of these 
160 patients Serum ALT and AST was found to be elevated in 43 
patients(27%), Serum alkaline phosphatase was found to be elevated in 10 
patients (6%), Serum bilirubin was found to be elevated in 4 patients (3%). 
                             
 
 
 
 
There was no significant alteration in serum protein or albumin 
globulin ratio. 
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1.  AGE DISTRIBUTION OF ABNORMAL ALT & AST: 
TABLE NO: 1 
                              ALT & AST 
Age Group  Abnormal  Normal 
30-40 yrs 0 (0%) 7 (100%) 
41-50 yrs 15 (31%) 33 (69%) 
51-60 yrs 23 (33%) 46 (67%) 
61-70 yrs 5 (15%) 28 (85%) 
71-80 yrs 0 (0%) 3 (100%) 
 
The mean age of patients with abnormal ALT and AST was 53.23 
yrs. 
2. SEX DISTRIBUTION OF ABNORMAL ALT & AST:   
TABLE NO:2                                                                                                                        
             ALT & AST 
Gender  Abnormal  Normal 
Female 25 (26%) 70 (74%) 
Male 18 (28%) 47 (72%) 
 
The abnormal ALT and AST was seen in 26%  of females and 28% of 
males.                                  
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3. BODY MASS INDEX DISTRIBUTION: 
TABLE NO: 3 
BMI               ALT & AST  
 Abnormal  Normal Pearson 
Chi square test of 
significance 
P value= 0.000 
Underweight 0 (0%) 2 (100%) 
Normal 1 (2%) 59 (98%) 
Over weight 22 (36%) 39 (64%) 
Obese 20 (54%) 17 (46%) 
 
The abnormal ALT and AST was seen in 36% of overweight patients 
and 54% of obese patients (p value =0.000).The mean BMI in patients with 
abnormal ALT and AST was 29.64 
4. WAIST HIP RATIO DISTRIBUTION: 
In total of 18 males who had elevated transaminases, 14 (77 %) of them 
had waist hip ratio >1. In total of 25 females who had elevated 
transaminases, 25(100%) of them had waist hip ratio >0.8.Thus the patients 
with abnormal ALT & AST was significantly associated with central 
obesity (p value 0.000). 
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5. SERUM CHOLESTEROL DISTRIBUTION: 
TABLE NO: 5 
  
 
 
ALT & AST  
Pearson chi  
square Test of 
significance  
P value =0.011
TOTAL CHOLESTEROL Abnormal  Normal 
TOTAL CHOLESTEROL 
<200 
20 (20%) 80 (80%) 
TOTAL CHOLESTEROL 
>=200 
23 (38%) 37 (62%) 
 
The elevated ALT & AST was common in 38% patients with serum 
cholesterol >200mg/dl, and it was statistically significant  
(p value=0.01). 
 
6. SERUM TRIGLYCERIDES DISTRIBUTION: 
TABLE NO: 6 
 
 
 
ALT & AST Pearson chi 
square test of 
significance 
P value =0.001 
TRIGLYCERIDES  Abnormal  Normal 
TRIGLYCERIDES 
>=180 
33 (38%) 54 (62%) 
TRIGLYCERIDES 
<180 
11 (04%) 63 (86%) 
The elevated transminases was more common in patients with serum 
triglyceride >180 mg/dl(p value =0.001). 
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7. In our study we found that 58 % of patients with abnormal ALT and 
AST was found to have low HDL<40 mg/dl which was found to be 
statistically insignificant (p value =0.22). 
8. The patients with abnormal ALT and AST was found to have poor 
glycemic control as evidenced by HBA1C.  88% of patient with abnormal 
ALT and AST have HBA1C >7%.  Mean HBA1C in patients with abnormal 
ALT and AST was 9.98% (p value =0.002). 
9. The mean duration of diabetes in patients with abnormal ALT and 
AST was 6.35yrs.  
10. Generally in NAFLD the ratio of AST to ALT is less than 1, but this 
ratio increases as fibrosis advances. In our study AST/ALT ratio <1 was 
seen in 31 patients(72%) and AST/ALT ratio >1 seen in 12 patients(28%). 
11. In our study we have noticed that 72(46%) patients with type 2 DM has 
USG evidence of fatty liver. Of this 72 patients 44% patients have normal 
ALT and AST and 56% had abnormal ALT and AST.. 
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CHART 1:  
AGE DISTRIBUTION 
 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 Total no patients =160; mean age of abnormal ALT & AST 
=53.23yrs 
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CHART 2: 
SEX DISTRIBUTION 
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 Total no of patients =160; 
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CHART 3: 
RELATIONSHIP BETWEEN BODY MASS INDEX AND ALT & AST 
LEVELS 
 
 
          
 
 
 
 
 
 
 
 
 
 
 
 
 
 Total no of patients=160; p value = 0.000 
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CHART 4: 
RELATIONSHIP BETWEEN SERUM CHOLESTEROL AND ALT & 
AST LEVELS 
 
 
          
 
 
 
 
 
 
 
 
 
 
 
 
 
 Total no of patients =160; p value = 0.011 
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CHART 5: 
RELATIONSHIP BETWEEN SERUM TRIGLYCERIDES AND ALT 
& AST LEVELS 
 
       
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Total no of patients =160; p value =0.001  
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DISCUSSION 
 
Because the liver plays a critical role in the maintenance of 
carbohydrate homeostasis, glucoregulation, and insulin degradation, it is not 
surprising that its functions may be affected as a result of diabetes mellitus 
58. Elevated activities of serum aminotransferases are a common sign of 
liver disease and are observed more frequently among diabetics than in the 
general population58.  
The prevalence of elevated transaminases levels in type 2 diabetes 
mellitus is not well known in the Indian population. In earlier studies, 
applying different methodology and enrolling variable population sample 
sizes as well as considering different cut-off values for ALT readings has 
yielded variable prevalence rates59,60,61,62. 
In our present study, prevalence of elevated ALT & AST was found 
in 27% of patients, elevated ALP was seen in 6% of patients and raised 
serum bilirubin in 3% of patients. There was no significant alteration in 
serum protein or albumin globulin ratio. 
According to a previous study conducted by Salmela et al 59, in type 2 
DM  prevalence of abnormal transaminases was found to be 22.9%  and 
raised serum bilirubin is 10.2% . Furthermore in a study conducted by   
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Sheriff Gonem et al63 in type 2 DM, reported a lower rate of prevalence of 
abnormal transaminases which was found to be 15.7%, raised ALP seen in 
10%, raised serum bilirubin in 3% individuals. 
In our study, elevated transaminases was seen 31%  of  patients in the 
age group of 41-50 yrs, 33% in the age group of 51-60 yrs and 15 % in the 
age group of 61-70 yrs. Supported by earlier studies, 64,65 this finding 
suggested that severe steatosis denoted by a higher release of the ALT 
enzyme in response to hepatocytes derangement, tends to occur earlier in 
the disease process. As a marker of hepatocyte integrity the ALT activity 
decreases as steatosis progresses. In our study the mean duration of diabetes 
in patients with abnormal transaminases is 6.34 yrs which was consistent 
with finding of Salmela et al59  and Layla Judi et a l67.  The prevalence of 
elevated transaminases level decreased with increased age and increased 
duration of diabetes.   
In our study elevated transaminases seen in 28% males and 26% 
females. However in our study we are not able to demonstrate significant 
sex difference in prevalence of abnormal transaminases,  Erbey et al.60  
reported prevalence rates of 10.7% and 5.3% in type 2 diabetic men and 
women respectively and West et al.66 reported a  rate of 12.1%; 14.4% in 
men and 9.3% in women with type 2 diabetes mellitus.  Erbey et al 60  and 
West et al 66  have demonstrated that  male gender is a independent predictor 
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of abnormal ALT levels which was also supported by Layla Judi67 et al in 
their study. 
In our study we have noticed that elevated transaminases was seen in 
36% of overweight category patient and 54% of obese category patients     
(p value =0.000). These findings are consistent with previous large scale 
studies by Salmela et al 59 and Erbey et al 60 who reported that prevalence of 
abnormal transaminases was common in  patients with  BMI >25 kg/m2 . 
Also in our study the patients with elevated transaminases was 
significantly associated with central obesity (p value 0.000) which was 
consistent with study conducted by Layla Judi et al67. This finding can be 
attributed to the fact that elevated ALT levels are more related to central fat 
distribution than to general obesity. The most obvious explanation for this is 
that in the presence of insulin resistance, the larger mass of adipose tissue in 
abdominally obese subjects causes an inappropriate suppression of lipolysis 
and increased flux of non-esterified free fatty acid from visceral fat to liver. 
Hence, there is an increase in the size of hepatic free fatty acid pool which 
favours the accumulation of triglycerides in the hepatocytes. The 
triglyceride overload provides abundant amounts of substrate for non-
oxidative pathways, in addition to causing mitochondrial dysfunction. These 
lipid-induced changes are believed to ultimately lead to cell apoptosis. 68,69  
   53
In our study patients we noticed that patients with elevated 
transaminases had a poor glycemic control as evidenced by HbA1C. Mean 
HBA1C in patients with elevated transaminases was 9.98 (p value =0.002), 
which was consistent with finding of Salmela et al59 who demonstrated a 
mean HBA1C OF 11.2% in patients with elevated transaminases indicating 
poor glycemic control.  
We have also observed like other people that raised transaminases is 
closely related to other features of metabolic syndrome in addition to type 2 
diabetes 70, like obesity and serum triglycerides more than180 mg/dl. 38% 
of our patients had a fasting serum triglycerides level of more than 180 
mg/dl which was found to be statistically significant (p value=0.001). Our 
results are consistent with findings of  Shahid ahmed et al71 who reported 
42.6% patients with elevated transaminases had serum triglycerides >180 
mg/dl.  
In our study we found that 58 % of patients with abnormal ALT and 
AST was found to have HDL<40 mg/dl which was found to be statistically 
insignificant (p value =0.22) which is consistent with finding of Layla Judi 
et al. 
In our study we found that elevated ALT & AST was common in 
patients with serum cholesterol >200mg/dl, and it was statistically 
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significant (p value=0.011) which was not consistent with finding of Shahid 
ahmed et al71  who reported that association of serum cholesterol and 
abnormal transaminases is statistically insignificant.  
  All patients with elevated transaminases   showed fatty liver on 
ultrasound and  Though we did not do liver biopsies in these patients, 
ultrasonographic appearance of fatty liver has a good predictive value for 
NAFLD.   It has already been established that mild to moderate elevation of 
serum aminotransferases is the most common laboratory abnormality in 
patients with non alcoholic fatty liver disease (NAFLD). NAFLD is the 
commonest cause of elevated aminotransferases in type 2 diabetic patients, 
and our study confirms that too.  In the United States, NAFLD is replacing 
alcohol and viral hepatitis as the most common aetiology of chronically 
elevated LFTs, in both diabetic and non diabetic individuals.   
Since all our patients included in our study were on Oral 
hypoglycaemic agents (metformin and sulphonylureas) ,we are not able to 
substantiate the difference in the  prevalence  of abnormal transaminases in 
insulin and OHA groups. The spectrum of NAFLD, including its severe 
form NASH, has been consistently associated with insulin resistance and 
hyperinsulinaemia72-74. This has raised a concern that treatment with insulin 
in type 2 diabetes may aggravate liver disease. Consistent with this, in data 
from de Marco et al75., the standardized mortality ratio from cirrhosis in 
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patients with type 2 diabetes was higher in those treated with insulin (OR 
6.8 vs. diet alone) than in those on oral hypoglycaemic agents (OR 4.9 vs. 
diet alone).75 However, both hyperglycaemia and hyperinsulinaemia can 
promote fatty infiltration of the liver. Long-standing type 2 diabetes may be 
associated with relative insulin deficiency, and appropriate insulin treatment 
would shift the balance against hepatic steatosis. However previous  study 
conducted by West et al66 and Salmela et al59, shows that insulin use may be 
protective against the effects of elevated ALT levels. Although this finding 
suggests that administration of insulin to diabetic patients may help to avoid 
harmful involvement of the liver by inflammation and fibrosis, it requires 
further investigation. 
Our study has limitations. Firstly, the prevalences of raised 
transaminases may still be underestimates.  A single estimation of ALT was 
used to define abnormality. Fluctuation in the ALT levels is recognized in 
patients with chronic liver disease, and a single measurement can 
underestimate disease burden76. Secondly,Since all our patients were on oral 
hypoglycaemic agents, we are not able to substantiate the difference in the  
prevalence  of abnormal transaminases in insulin and OHA groups.Thirdly, 
In our study we didn’t do a liver biopsy as most of the patients being 
asymptotatic denied consent for invasive procedure. Lastly, as the study 
included patients attending their hospital review, there is likely to be some 
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selection bias. A variety of factors including referral pattern and poor 
control can influence the selection of patients for regular hospital review. 
Although we have controlled for this to some extent by including HBA1C in 
our analysis, findings of current study well required confirmation in 
population based studies.    
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SUMMARY 
• In our present study, prevalence of elevated ALT & AST was found 
in 27% of patients, elevated ALP was seen in 6% of patients and 
raised serum bilirubin in 3% of patients. There was no significant 
alteration in serum protein or albumin globulin ratio. 
• The prevalence of abnormal transaminases in type 2 DM decreases 
with increasing age i.e: more common in younger age group and also 
decreases with increase in duration of diabetes. 
• Though we are not able to demonstrate significant sex difference in 
prevalence of abnormal transaminases, previous studies have 
demonstrated that male gender is a independent predictor of abnormal 
ALT levels 
• The prevalence of abnormal transaminases was more common in 
patients with BMI > 25 kg/m2 and also in patients with central 
obesity. 
• The patients with abnormal transaminases was found to have poor  
glycemic control as evidenced by HBA1C. 
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• We have also observed like other people that raised transaminases is 
closely related to other features of metabolic syndrome in addition to 
type 2 diabetes , like obesity and serum triglycerides more than180 
mg/dl. 
• All patients with elevated transaminases   showed fatty liver on 
ultrasound.  
• NAFLD is the commonest cause of elevated aminotransferases in 
type 2 diabetic patients, and our study confirms that too.  
• These findings necessitate interference by lifestyle modification and 
early therapeutic measures to control risk factors, especially obesity, 
in younger diabetics which might help to prevent chronic liver 
disease. 
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CONCLUSION 
A high proportion of patients with diabetes mellitus in our catchment 
population have abnormal liver function tests that may be a marker for  
NASH and  insulin resistance. Currently, routine liver function screening is 
not being advocated in type 2 diabetics but emerging evidence suggests that 
abnormal LFT may be a marker for metabolic syndrome and insulin 
resistance in type 2 diabetes. Such patients would thus warrant more 
intensive metabolic control particularly of their hyperglycaemia and 
dyslipidaemia and also their obesity and hypertension to not only reduce 
cardiovascular risk attributed to by their insulin resistance but also to 
prevent progression to significant hepatic dysfunction like cirrhosis and 
hepato-cellular carcinoma.                  
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PROFORMA 
NAME:                                                 
I.P/O.P.NO:                                 
AGE:           yrs.                           
SEX: Male/Female. 
OCCUPATION: 
ADDRESS: 
 
HEIGHT:        cm.   WEIGHT:       kg.      BMI: 
WAIST:         cm.    HIP:         cm.     WAIST HIP RATIO: 
DURATION OF DIABETES MELLITUS: 
ON TREATMENT WITH 
 
PRESENCE OF COMORBID ILLNESS: 
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 Hypertension /Coronary heart diseases /chronic kidney diseases 
/tuberculosis /chronic obstructive   pulmonary diseases/cerebrovascular 
accidents /Epilepsy / chronic liver diseases. 
ANYOTHER ILLNESS: 
DRUG HISTORY: 
 
 
PERSONAL HISTORY: 
 
FAMILY HISTORY: 
 
EXAMINATION OF THE PATIENT: 
 
INVESTIGATION: 
HBSAg:                        ANTIHCV:                  HIV ELISA: 
BLOOD SUGAR:                                  HbA1C: 
BLOOD UREA:                        SERUM CREATININE: 
LIVER FUNCTION TEST:    
SERUM BILIRUBIN:                DIRECT:          INDIRECT: 
AST:              ALT:                     ALP: 
SERUM PROTEIN:                ALBUMIN:         GLOBULIN: 
SERUM LIPID PROFILE: 
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TOTAL CHOLESTEROL:                    
HDL:                LDL:               VLDL: 
TRIGLYCERIDES: 
ULTRASOUND ABDOMEN: 
 
   75
ABBREVIATIONS 
DM   –  Diabetes mellitus 
NAFLD  –  Non alcoholic fatty liver diseases. 
NASH  –  Non alcoholic steatohepatitis 
HCV   –  Hepatitis C virus 
HCC   –  Hepatocellular carcinoma 
GH   –  Glycogenic hepatopathy 
DHS   –  Diabetic hepatosclerosis 
CVD   –  Cardiovascular disease  
CAD   –  Coronary heart diseases 
HT   –  Hypertension 
COPD  –  Chronic obstructive pulmonary diseases 
CVA   –  Cerebrovascular accidents 
LFT   –  Liver function tests 
 ALT   –  Alanine transaminase 
AST   –  Aspartate transaminase 
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ALP   –  Alkaline phosphatase 
GGT   –  Gamma glutamyl transferase 
T.PRO  –  Total protein 
ALB   –  Albumin 
GLO   -  Globulin  
CHOL  –  Cholesterol 
TGL   –  Triglyceride 
HDL   –  High density lipoprotein 
LDL   –  Low density lipoprotein 
VLDL  –  Very low density lipoprotein 
USG   –  Ultra sound 
HBA1C  –  Glycosylated haemoglobin 
BMI   –  Body mass index 
WHR  –  Waist hip ratio 
HBSAg  –  Hepatitis surface antigen 
ANTI HCV –  Hepatitis C virus antibody 
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HIV   –  Human immunodeficiency virus 
TNF α  –  Tumor necrosis factor α 
UDCA  –  Urso deoxycholic acid 
SAMe  –  S adenosyl methionine. 
MF   –  Metformin 
G   –  Glibenclamide 
GM   –  Glimepride 
GZ   -  Glipizide 
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